Researchers have recently become interested in developing immunotherapies for the treatment of non-small cell lung cancer (NSCLC), particularly monoclonal antibodies targeting the programmed cell death-1 (PD-1) receptor and its ligand (PD-L1) [1, 2]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.